News and Trends 9 Sep 2019 4BIO Capital Raises €45M Fund to Invest in Advanced Therapies The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will […] September 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Top Cardiology Biotech News from the ESC Conference 2019 Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […] September 5, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Orchard’s Gene Therapy Improves Children’s Motor Ability Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […] September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2019 US Genomics Firm Combines with Curetis to Tackle Antibiotic Resistance The German biotech Curetis has been combined with the US genomics company OpGen to pool their molecular diagnostics expertise in the fight against antibiotic resistance. “After more than one year of intensive discussions and negotiations for many months, it feels great to be able to announce the transaction today,” Oliver Schacht, the CEO of Curetis, […] September 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2019 Gyroscope Targets Age-Related Blindness with €55M Series B UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […] September 3, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2019 UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […] September 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2019 HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs The French biotech HiFiBiO has raised €60M in a Series C round to finance the development of antibody drugs for cancer and autoimmune diseases based on its single-cell screening technology. HiFiBiO will use the money to accelerate the progress of its drugs to clinical trials, though it has not specified when it plans to begin […] August 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2019 Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II An off-the-shelf cancer immunotherapy developed by the Swedish biotech Immunicum has eradicated kidney tumors in 11% of treated patients compared with just 4% of patients given standard treatments in a phase II trial. Immunicum is developing a cell immunotherapy to treat metastatic renal cell carcinoma. This advanced form of kidney cancer is particularly hard to […] August 29, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Type 1 Diabetes Immunotherapy Shows Promise in Phase I An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Aug 2019 Swedish Ulcerative Colitis Treatment Makes Phase II Comeback InDex Pharmaceuticals’ ulcerative colitis drug candidate has achieved positive phase IIb results, suggesting work to improve its dosage after a previous phase III failure was successful. The Swedish company tested different doses of the small molecule drug cobitolimod against a placebo in patients with the inflammatory bowel disease ulcerative colitis. The 213 patients in the […] August 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2019 Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […] August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email